Liposomes for drug delivery in stroke.

Abstract

Stroke is one of the leading causes of mortality and morbidity worldwide. Due to its poor prognosis, there is a major negative impact on the patients and their family's life quality. However, despite the severity of this pathology tissue plasminogen activator (tPA) is the only FDA approved treatment for ischemic stroke. Moreover, there is no effective treatment for hemorrhagic stroke and only some palliative procedures are often performed to improve the patient's quality of life. Considering this, nanotechnology can offer some advantages for the development of new therapies for stroke. Among the various types of nanomaterials, liposomes are the most extensively studied due to their biocompatibility, biodegradability, and low toxicity. Liposomes, as a drug delivery system, are able to mask therapeutic compounds and allow their passage through the blood-brain barrier. Liposomes also protect drugs from degradation in a biological environment, increasing the circulation time and accumulation in the target tissue. Hence, this review highlights the potential of liposomes applications for delivery of therapeutic compounds for treating stroke.

• Authors: Gisele E Bruch, Lorena F Fernandes, Beatriz L T Bassi, Marco Túllio R Alves, Isabelle O Pereira, Frédéric Frézard, André R Massensini
• Journal: Brain research bulletin (Brain Res Bull) Vol. 152 Pg. 246-256 (10 2019) ISSN: 1873-2747 [Electronic] United States
• PMID: 31323280 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Liposomes
• Tissue Plasminogen Activator

Topics

• Animals
• Blood-Brain Barrier (drug effects)
• Brain Ischemia (drug therapy)
• Disease Models, Animal
• Drug Delivery Systems (methods)
• Humans
• Liposomes (metabolism, therapeutic use)
• Quality of Life
• Stroke (drug therapy)
• Tissue Plasminogen Activator (pharmacology)